Biological Assembly 1  

 3D View: Structure | 1D-3D View | Validation Report

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 21.48 kDa 
• Atom Count: 1515 
• Modelled Residue Count: 192 
• Deposited Residue Count: 192 
• Unique protein chains: 2

2M5B

The NMR structure of the BID-BAK complex

• PDB DOI: 10.2210/pdb2M5B/pdb
• BMRB: 19045

• Classification: APOPTOSIS
• Organism(s): Homo sapiens, synthetic construct
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2013-02-19 Released: 2013-04-17 
• Deposition Author(s): Moldoveanu, T., Grace, C.R., Kriwacki, R.W., Green, D.R.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Literature

BID-induced structural changes in BAK promote apoptosis.

Moldoveanu, T., Grace, C.R., Llambi, F., Nourse, A., Fitzgerald, P., Gehring, K., Kriwacki, R.W., Green, D.R.

(2013) Nat Struct Mol Biol 20: 589-597

• PubMed: 23604079 
• DOI: 10.1038/nsmb.2563
• Primary Citation of Related Structures:  
  2M5B


• PubMed Abstract: 
  

The BCL-2-family protein BAK is responsible for mitochondrial outer-membrane permeabilization (MOMP), which leads to apoptosis. The BCL-2 homology 3 (BH3)-only protein BID activates BAK to perform this function. We report the NMR solution structure of the human BID BH3-BAK complex, which identified the activation site at the canonical BH3-binding groove of BAK. Mutating the BAK BH1 in the groove prevented activation and MOMP but not the binding of BID. BAK BH3 mutations allowed BID binding and activation but blunted function by blocking BAK oligomerization. BAK activation follows a 'hit-and-run' mechanism whereby BID dissociates from the trigger site, which allows BAK oligomerization at an overlapping interface. In contrast, the BH3-only proteins NOXA and BAD are predicted to clash with the trigger site and are not activators of BAK. These findings provide insights into the early stages of BAK activation.

---

Organizational Affiliation: 

Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Bcl-2 homologous antagonist/killer	A	169	Homo sapiens	Mutation(s): 0  Gene Names: BAK, BAK1, BCL2L7, CDN1
UniProt & NIH Common Fund Data Resources
Find proteins for Q16611 (Homo sapiens) Explore Q16611  Go to UniProtKB:  Q16611
PHAROS:  Q16611

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
human_BID_BH3_SAHB	B	23	synthetic construct	Mutation(s): 0
UniProt & NIH Common Fund Data Resources
Find proteins for P55957 (Homo sapiens) Explore P55957  Go to UniProtKB:  P55957
PHAROS:  P55957

Small Molecules

Modified Residues  2 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
MK8	B	L-PEPTIDE LINKING	C7 H15 N O2		LEU
NLE	B	L-PEPTIDE LINKING	C6 H13 N O2		LEU

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 
• OLDERADO: 2M5B Olderado

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2013-02-19 
• Released Date: 2013-04-17 
Deposition Author(s): Moldoveanu, T., Grace, C.R., Kriwacki, R.W., Green, D.R.

Revision History  

• Version 1.0: 2013-04-17
  Type: Initial release
  
• Version 1.1: 2013-05-08
  Changes: Database references
• Version 1.2: 2013-05-22
  Changes: Database references